|
|
The 4th World Congress on
Controversies in Urology (CURy)
Paris, France, January 27-30, 2011 |
|
 |
| Scientific Program |
 |
|
|
|
08:30-10:00
Hall A |
LESS Surgery
(Supported by an unrestricted grant of Olympus Medical Systems GMBH)
|
| Chairpersons: |
A. Alcaraz, Spain; E. Barret, France
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00 |
LESS: What is new?
J.-U. Stolzenburg, Germany
LESS in Urological Surgery
A. Figueiredo, Portugal
LESS: Transvaginal nephrectomy
A. Alcaraz, Spain
LESS: Radical Prostatectomy
F. Gaboardi, Italy
LESS and Robotics
E. Barret, France
Q&A
|
|
08:30-10:00
Hall B |
Diagnosis & Imaging of Prostate Cancer
|
| Chairpersons: |
N. Fleshner, Canada; P. Mozer, France
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00 |
Prostate Biopsy: Update
N. Fleshner, Canada
PCA3 and other tissue biomarkers: Current status
A. De La Taille, France
PSA, SNP and other New Markers
A. Zlotta, Canada
MRI in early PCA
A. Villers, France
Histoscanning
J. Braeckman, Belguim
Q&A
|
|
10:00-10:30 |
Coffee Break & Poster Viewing |
|
|
Treating Bone Disease across the Prostate Cancer Continuum of Care
(Supported by an unrestricted grant of Amgen)
|
|
Chairpersons: |
N. Clarke, UK; M. Colombel, France
|
|
|
The silent risk of cancer treatment induced bone loss (CTIBL): How should we manage our patients on ADT?
J. Brown, UK
RANK Ligand inhibition: Challenging the standard of care for bone health in men with advanced prostate cancer
K. Fizazi, France
Extending bone-metastases free survival in men with prostate cancer: Future prospects with RANK Ligand inhibition
S. Oudard, France
|
|
10:30-12:00
Hall B |
Non-Muscle Invasive Bladder Cancer (NMIBC): White light cystoscopy, blue light cystoscopy, narrow band imaging, virtual cystoscopy?
What should the urologist use in 2011?
A Case Discussion Panel
(Supported by an unrestricted grant of GE Healthcare) |
|
Chairpersons: |
J.A. Witjes, The Netherlands; A. Zlotta, Canada
|
|
10:30-10:45
10:45-11:05
11:05-11:25
11:25-11:45
11:45-12:00 |
The value of cytology, pathological limitations of staging and grading of NMIBC and CIS
E. Comperat, France
Narrow-band imaging (NBI)
T. De Reijke, The Netherlands
Virtual cystoscopy and 3D reconstruction of the Upper Urinary Tract (UUT)
A. Stenzl, Germany
A new in-bladder device for follow-up: Wireless Capsule Endoscopy
A. Neheman, Israel
Hexaminolevulinate guided fluorescence cystoscopy (PPD) and thermo-chemotherapy
J.A. Witjies, The Netherlands
|
|
12:00-13:30
Hall A |
Multidisciplinary Care in Prostate Cancer: Decrease the Barriers and Grasp the Benefits
(Satellite Symposium sponsored by Astellas Pharma Europe Ltd.)
|
|
Chairperson: |
J. Irani, France
|
|
|
Introduction
Chair
Multidisciplinary care in prostate cancer: View of the surgeon
P. Bastian, Germany
Multidisciplinary care in prostate cancer: View of the radiation oncologist
M. van Vulpen, The Netherlands
Multidisciplinary care in prostate cancer: View of the brachytherapist
J.-M. Cosset, France
Multidisciplinary care in prostate cancer: Benefits for the patient
B. Tombal, Belgium
Discussion and take home messages
Chair, faculty & participants
|
|
14:30-16:00
Hall A |
The Challenge of Managing Male LUTS: Do the Guidelines Provide Real Guidance?
(Supported by an unrestricted grant of Astellas Pharma Europe Ltd.)
|
|
Chairpersons: |
F. Desgrandchamps, France & J. Fitzpatrick, Ireland
|
|
14:30-15:00
15:00-15:30
15:30-16:00 |
Controversy 1: Diagnosis of male LUTS: Piece of cake!
M. Oelke, Germany
Controversy 2: Individualizing treatment for male LUTS is the future!
E. Chartier-Kastler, France
Controversy 3: Why bother treating storage symptoms in men?
C. Llorente, Spain
|
|
14:30-16:00
Hall B |
Low Risk Prostate Cancer: The case of active surveillance and focal therapy
(Partially supported by an unrestricted grant form Steba Biotech)
|
|
Chairpersons |
L. Klotz, Canada; A. Villers, France
|
|
14:30-14:45
14:45-16:00
14:45-14:52
14:52-15:00
15:00-15:08
15:08-15:16
15:16-15:24
15:24-15:32
15:32-15:40
15:40-16:00 |
Active surveillance
L. Klotz, Canada
Which focal therapy? Panel discussion
Moderator:
A. Villers, France
Pathological basis for focal therapy
A. Villers, France
HIFU in low risk prostate cancer
C. Robertson, USA
In bore MR guided robot assisted focal laser therapy of prostate cancer
J. Trachtenberg, Canada
Cryo-ablation in low risk prostate cancer
U. Witzsch, Germany
Vascular targeted photodynamic therapy with TOOKAD® Soluble in patients with low risk prostate cancer
M. Emberton, UK
Correlation between histological results and MR imaging after vascular targeted photodynamic therapy with TOOKAD® Soluble in focal therapy
A.R. Azzouzi, France
The case against active surveillance and focal treatment
M. Graefen, Germany
Discussion
|
|
16:00-16:30 |
Coffee Break & Poster Viewing |
|
16:30-18:00
Hall A |
A Multidisciplinary Treatment Team Approach to Metastatic Hormone-Refractory Prostate Cancer
(Satellite Symposium sponsored by Sanofi-Aventis)
|
| Chairpersons: |
F. Saad, Canada; S. Oudard, France
|
|
16:30-16:35
16:35-17:00
17:00-17:25
17:25-17:50
17:50-18:00 |
Welcome and Introduction
F. Saad, Canada
Treatment of high-risk patients with advanced prostate cancer using a multi-disciplinary approach
B. Tombal, Belgium
C. Sternberg, Italy
Management of mHRPC patients previously treated with docetaxel -
Critical analysis of the data
S. Oudard, France
Management of mHRPC patients previously treated with docetaxel -Practical Application of the data M. Eisenberger, USA
Group discussion and meeting close
F. Saad, Canada
S. Oudard, France
All
|
|
16:30-18:00
Hall B |
Localized Kidney Cancer
|
| Chairpersons: |
G. Morgia, Italy; M. Soloway, USA
|
|
16:30-16:45
16:45-18:00 |
Are there still contraindications to partial nephrectomy?
J. Patard, France
Case Discussion Panel: 3cm tumor in a 70-year old patient
Case presenter:
G. Morgia, Italy
Discussants:
The place for
...Surveillance
J. Patard, France
...Ablative minimally invasive treatment
B. Malavaud, France
...Open Surgery
Z. Dotan, Israel
...Laparoscopy
A. Finelli, Canada
...Robotic
C. Vaessen, France
|
| Saturday, January 29, 2011 |
|
08:30-10:00
Hall A |
Hot News from 2010 Congresses
|
| Moderator: |
L. Boccon-Gibod, France; R. Burette, Belgium; K. Fizazi, France
|
|
08:30-09:00
09:00-09:30
09:30-10:00
|
Prostate cancer
J. van Moorselaar, The Netherlands
Bladder cancer
J. Irani, France
Renal cancer
A. Alcaraz, Spain
|
|
08:30-10:00
Hall B |
Surgical Treatment of Female Stress Urinary Incontinence
|
|
Chairpersons: |
F. Cruz, Portugal; V. Delmas, France
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
|
Retropubic and transobturator tension-free suburethral slings: What have we achieved in the past 15 years?
E. Costantini, Italy
Small is beautiful? Can single incision suburethral slings compare to tension-free slings?
F. Cruz, Portugal
Which risk factors can affect the success of suburethral slings? What should we tell our patients:
J. Heesakkers, The Netherlands
Dysfunctional voiding after a suburethral sling: How can it be prevented, detected and treated:
V. Delmas, France
Do bulking agents/balloons have a place in the treatment of female SUI?
D. Yachia, Israel
Do MUS have an effect on female sexual function?
E. Costantini, Italy
Discussion & Conclusions
|
|
10:00-10:30 |
Coffee Break & Poster Viewing |
|
10:30-12:00
Hall A |
GnRH-receptor blockers: A new era for GnRH analogues?
(Supported by an unrestricted educational grant from Ferring Pharmaceuticals)
|
| Chairpersons |
C. Schulman, Belguim; L. Boccon-Gibod, France |
| |
|
| 10:30-10:35 |
Welcome and Objectives
L. Boccon-Gibod, France |
| |
|
| 10:35-10:55 |
Development of a new GnRH blocker
B.-E. Persson, Switzerland |
| |
|
| 10:55-11:15 |
Locally advanced prostate cancer: The role of surgery in combination treatments.
F. Montorsi, Italy |
| |
|
| 11:15-11:35 |
Androgen deprivation with radiation: When? For how long?
M. Mason, UK |
| |
|
| 11:35-11:55 |
What patients benefit from a GnRH blocker?
T. Keane, USA |
| |
|
| 11:55-12:00 |
Conclusions
C. Schulman, Belgium
|
|
10:30-12:00
Hall B |
Muscle Invasive Bladder Cancer: Is There a Place for Conservative Management?
|
|
Capsule: |
Role of a strong multidisciplinary collaboration |
|
Chairperson: |
M. Soloway, USA & A. Stenzl, Germany
|
|
10:30-12:00
|
A debate and case panel discussion: A multidisciplinary team approach
PRO
R. Burette, Belgium
N. Clarke, UK
A. Zlotta, Canada
CON
Y. Fradet, Canada
U. Studer, Switzerland
M. Zerbib, France
|
|
12:00-13:30
Hall A |
Urologists, RCC and targeted agents: Applying Clinical Evidence to Clinical Practice
(Satellite Symposium sponsored by Pfizer Oncology)
|
| |
Welcome and introduction
C. Sternberg, Italy
Selecting Targeted Agents for the Treatment of Advanced RCC
C. Sternberg, Italy
Getting the Best from Targeted Agents in Clinical Practice: The Importance of Therapy Management
M. Kuczyk, Germany
Current and Future Role in Surgery in the Era of Targeted Agents
A. Bex, The Netherlands
Discussions and Q&A
Panel
Summary and close
C. Sternberg, Italy
|
|
14:30-16:00
Hall A |
Is the Gold Standard turning Green? Breakthrough Innovation in GreenLight
(Satellite Symposium sponsored by American Medical Systems)
|
| Chairperson: |
A. Bachmann, Switzerland
|
|
|
Why do we need more and more laser to treat BPH?
O. Reich, Germany
GreenLight HPS laser for the treatment of BPH: functional results with long-term follow-up
G. Alivizatos, Greece
The speed of light just went faster
F. Gomez Sancha, Spain
Is GreenLight XPS as fast and safe as TURP?
A. Bachmann, Switzerland
Prostate surgery - the transition from PV to XPS J.A. Thomas, UK
Is GreenLight XPS now better for the patients or the surgeons?
O. Reich, Germany
|
|
14:30-16:00
Hall B |
Kidney Stone & Endourology
|
|
Chairpersons: |
D. Tolley, UK; O. Traxer, France
|
|
14:30-15:00
15:00-15:30
15:30-16:00
|
Indications for Mini-Perc vs. Flexible URS: A debate
(Debate sponsored by Karl Storz)
Mini Perc: T. Knoll, Germany
Flexible URS: O. Traxer, France
Management of ureteral impacted stone: ESWL vs. URS vs. Lap surgery
ESWL: D. Tolley, UK
URS: O. Traxer, France
Lap surgery: H. Winkler, Israel
ESWL: Can we improve outcomes?
With novel technologies?
Clinically: Patient selection, patient stone factors
D. Tolley, UK
O. Traxer, France
H. Winkler, Israel
|
|
16:00-16:30 |
Coffee Break & Poster Viewing |
|
16:30-17:30
Hall A |
New Drugs and Technology Coming Soon to Your Practice
|
|
Chairpersons: |
P. Rischmann, France; R. Vela Navarrete, Spain
|
|
16:30-16:40
16:40-16:50
16:50-17:00
17:00-17:10
17:10-17:20
17:20-17:30
|
Uro-oncology: From our Bench to your Bedside
E. Baskin-Bey, UK
Provenge
K. Fizazi, France
Abiraterone in castration resistant prostate cancer
G. Attard, UK
A unique profile makes Silodosin different
F. Montorsi, Italy
Sacral neuro-stimulation in idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO)
E. Chartier-Kastler, France
Botox in idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO)
F. Cruz, Portugal
|
|
16:30-17:30
Hall B |
BPH Surgery: Gold Standard Surgery vs. Novel Technologies
|
|
Chairpersons: |
G. Alivizatos, Greece; M. Zerbib, France
|
|
16:30-17:30
16:30-16:40
16:40-16:50
16:50-17:00
17:00-17:10
17:10-17:20
17:20-17:30
|
Surgery for prostate 80 gram or more
Open simple prostatectomy: M. Zerbib, France
TURP: A. Skolarikos, Greece
TUR in saline: P. Geavlete, Romania
Green light laser: P. Whelan, Canada
Laser enucleation/HoLEP: R. Saglam, Turkey
Discussion
|
|
09:00-09:30
09:30-11:00
Hall A |
State of the Art: Patient safety and quality control is mandatory in urology
N. Fleshner, Canada
Nerve-Sparing Radical Prostatectomy: How I do it
Open vs. Laparoscopic vs. Robotic
|
|
Chairpersons: |
P. Coloby, France; F. Montorsi, Italy
|
|
09:30-11:00
|
HOW I DO IT: Videoclips
Pelvic lymphadenectomy
A. De La Taille, France
S. Egawa, Japan
H. Huland, Germany
F. Montorsi, Italy
Control of Santorini's plexus
C. Abbou, France
J. Moul, USA
T. Piechaud, France
Nerve-sparing extirpation of the prostate
C. Barre, France
A. De La Taille, France
S. Egawa, Japan
H. Huland, Germany
T. Piechaud, France
Dissection of seminal vesicles
C. Abbou, France
F. Montorsi, Italy
J. Moul, USA
Bladder neck dissection
C. Barre, France
S. Egawa, Japan
T. Piechaud, France
Panel discussion
Nerve-sparing: Why open should not be considered dead
H. Huland, Germany & J. Moul, USA
Nerve-sparing: Why laparoscopic should not be considered dead
C. Abbou, France & S. Egawa, Japan
Nerve-sparing: Why robotics will kill everything else
T. Piechaud, France & A. De La Taille, France
|
|
11:30-13:00
Hall A |
Radical Cystectomy: How I do it
Open vs. Laparoscopic vs. Robotic
|
|
Chairpersons: |
R. Hautmann, Germany; M. Soloway, USA; U. Studer, Switzerland
|
|
11:30-13:00 |
Open Sugery
R. Hautmann, Germany
A. Stenzl, Germany
U. Studer, Switzerland
Laparoscopic surgery
C. Abbou, France
F. Rozet, France
Robotic surgery
A. Mottrie, Belgium
C. Vaessen, France
Summary discussion
|
|
13:00-13:30 |
Drinks and Sandwiches |
|
|
|
|
WebStudio.co.il